Why are Medicare and Medicaid shown separately instead of combined?

They come from two different CMS data sources with no shared claim identifier, so they can't be reconciled into one number without double-counting or guessing. Every table and chart on this page keeps them fully separate.

Why is there no private/commercial revenue figure?

Private and commercial payer data comes from Transparency in Coverage files, which only publish negotiated rates — not claims or utilization volume. Without a volume figure, no revenue number can be computed for any provider from that data.

What does "Rank" mean in the Competitive Analysis & Benchmarks tables?

For a given CPT/HCPCS code, it's this provider's position by claims volume among all providers billing that same code at that geography level (State, National, or Pennsylvania for Medicaid) — rank 1 means the highest claims volume for that code.

Why is the Medicaid comparison limited to Pennsylvania only?

Medicaid is administered per-state with no single national fee schedule, so a state or national comparison the way Medicare has one isn't available. Pennsylvania (this provider's own state) is the only grouping that's conceptually meaningful.

Why are the numbers rounded to the nearest 10?

To avoid implying more precision than the underlying data supports at a single-provider level. Ratios are kept precise since they're a relative comparison, not a volume or dollar figure.

How current is this data?

The Medicare and Medicaid tables are both single current snapshots, not refreshed on a recurring schedule yet.

Saurin Mehta (NPI 1245394295)

Field	Value
Entity Type	Individual
Organization	Saurin Mehta
Address	2760 Century Blvd
City	Wyomissing
State	PA
ZIP	19610
Taxonomy	Specialist
NPI Enumerated	December 21, 2006

Payer Source	Total Paid
Medicare	$2.6M
Medicaid	$0

Key Findings

This provider’s Medicare activity is concentrated in high-cost biologic injectables: J3262, J0897, and J0129 together account for 59.3% of total Medicare revenue. Those three codes individually represent $781.2K (29.7%), $396.4K (15.1%), and $380K (14.5%) of Medicare revenue respectively, indicating the practice’s revenue base is heavily driven by parenteral specialty pharmaceuticals rather than routine office E/M or diagnostics.

The code mix (dominant use of J3262, J0897, J0129 plus additional billing for J0717, J3111, J1602, J1745) signals an operation oriented around chronic biologic therapy administration and management. Coupled with billing for injection/infusion administration codes (e.g., 96372 and 96413) and procedure codes for joint injections (20611, 20610), the pattern is consistent with a specialty infusion/clinic model delivering physician‑supervised injectable therapies for inflammatory and bone conditions.

Competitive standing is strong for specific biologics: J3262 ranks #17 of 618 providers nationally (97th percentile) and J0897 ranks #230 of 10057 providers nationally (98th percentile), both labeled as “notably above typical national volume.” By contrast, J0129 is in the 66th percentile (rank #412 of 1221) and is described as a typical volume for that code, so the provider is a national high-volume distributor for select drugs but otherwise a more ordinary participant for other biologics.

Several administration and office-visit codes are also above typical national volumes, which supports the interpretation of a high-throughput infusion practice. 96372 is an extreme outlier (rank #722 of 58224, 99th percentile) and 99214 is notably above typical volume (rank #18862 of 479517, 96th percentile), indicating outsized use of injection/administration procedures and moderate-level E/M visits relative to most peers.

Revenue scale and payer mix are effectively single‑payer: the provider’s lifetime Medicare revenue is $2.6M while there is no Medicaid billing on file. This lack of Medicaid activity means Medicare dominates both clinical volume and revenue, which may concentrate payer risk and influence contracting dynamics tied primarily to Medicare reimbursement policies.

The practice shows diversified ancillary services that support infusion care, including diagnostic and monitoring codes such as 77080 (DXA, $6.9K), 82306 (vitamin D testing, $2.8K), and routine lab/venipuncture codes (36415, $1.9K). These smaller revenue lines suggest on-site testing and bone-density monitoring that complement biologic therapy management rather than serving as primary revenue drivers.

While biologic drug administration drives the majority of revenue, many other codes fall in typical national ranges, indicating the provider is specialized rather than broadly dominant across multiple service lines. Examples include 96413 (chemotherapy administration) at the 86th percentile and multiple infusion/infusion‑related add‑ons (96401, 96365, 96415) in the typical percentile bands, supporting a focused infusion practice profile instead of a full-service oncology or multi-specialty center.

The provider has long-standing enrollment in Medicare, with an NPI enumerated on 2006-12-21 (~20 years ago), which suggests an established practice history. Combined with the concentrated biologic revenue and above-typical national volumes for specific injectable drugs, this tenure supports the interpretation of a mature specialty clinic with a stable, biologic-centric patient base.

Medicare: Complete Services Breakdown

The CPT/HCPCS codes generating the most Medicare revenue for this provider.

56 rows

CPT/HCPCS Code	Description	Claims	Avg Paid	Revenue
J3262	Injection, tocilizumab, 1 mg	156,240	$10	$781.2K
J0897	Injection, denosumab, 1 mg	22,020	$20	$396.4K
J0129	Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered)	11,180	$30	$379.9K
J0717	Injection, certolizumab pegol, 1 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered)	85,200	$1	$340.8K
J3111	Injection, romosozumab-aqqg, 1 mg	28,770	$10	$230.2K
J1602	Injection, golimumab, 1 mg, for intravenous use	16,750	$10	$167.5K
J1745	Injection, infliximab, excludes biosimilar, 10 mg	5,130	$30	$128.3K
99214	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the…	810	$90	$70.6K
96413	Chemotherapy is a therapeutic procedure used for the treatment of cancer via the use of chemical agents. These chemical agents (drugs) work on the cancerous cells of the body to destroy them. These…	420	$90	$36.8K
99213	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a low level of medical decision making, and/or the…	300	$60	$19.3K

Showing 1–10 of 56

Medicare: Competitive Analysis & Benchmarks

How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 56 CPT/HCPCS codes.

View: State1 / 2

Claims Volume vs. Pennsylvania Distribution

Saurin Mehta — 4 of 25 codes billed far more than typical (above p95)

p5–p95 (all providers)p25–p75MedianThis providerOutlier

Rank Distribution — Pennsylvania

Full comparison — all codes billed, vs. state median

56 rows

CPT/HCPCS Code	Rank	Provider Count	Median Claims	Avg Paid	Average Revenue
J0129	17	60	7,900	$30	$353.8K
J3262	2	30	45,000	$1	$268K
J0717	13	70	38,610	$1	$223.7K
J1602	22	60	11,780	$10	$181.6K
J3111	14	60	16,590	$10	$176.8K
J1745	25	80	3,630	$30	$115.4K
J0897	12	530	2,460	$20	$89.6K
80307	87	100	300	$60	$42.6K
83970	21	40	60	$40	$24.4K
80053	170	220	110	$10	$21.6K

Showing 1–10 of 56

Related Providers

Other providers that share a Tax Identification Number (TIN) with Saurin Mehta, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Michael Borofsky	PA	Specialist	$1.8M	$0
Nancy Walker	PA	Rheumatology Physician	$1.7M	$0
Peter Nicholas	PA	Specialist	$1.1M	$0
Peter Nicholas	PA	Rheumatology Physician	$219.1K	$0
Kristie Pepper	PA	Rheumatology Physician	$129.2K	$2.4K

Nearby Providers

Other providers in the same ZIP code as Saurin Mehta, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Bayada Home Health Care, Inc.	PA	Home Health Agency	$0	$18.5M
Holcomb Associates, Inc.	PA	Community/Behavioral Health Agency	$0	$11.1M
Paragon Behavioral Health Services, LLC	PA	Community/Behavioral Health Agency	$0	$10.8M
Patient First Pennsylvania Medical Group PLLC	PA	Family Medicine Physician	$0	$5.6M
Barry Malloy	PA	Retina Specialist (Ophthalmology) Physician	$3.3M	$1.8K
Anastasia Traband	PA	Retina Specialist (Ophthalmology) Physician	$3.1M	$14K
The Reading Hospital Surgicenter At Spring Ridge LLC	PA	Ambulatory Surgical Clinic/Center	$330.9K	$2.3M
Pennsylvania Eye & Ear Surgery	PA	Ambulatory Surgical Clinic/Center	$2.1M	$252.9K
Jeremy Aikey	PA	Ophthalmology Physician	$2.3M	$0
Berks Center For Digestive Health, LP	PA	Ambulatory Surgical Clinic/Center	$1.6M	$653.1K

Saurin Mehta — Billing Profile & Reimbursement Data

Sign up for Saurin Mehta — Billing Profile & Reimbursement Data policy alerts

Saurin Mehta — Billing Profile & Reimbursement Data

Sign up for Saurin Mehta — Billing Profile & Reimbursement Data policy alerts

Key Findings

Medicare: Total Revenue Breakdown by CPT/HCPCS Code

Medicare: Complete Services Breakdown

Medicare: Competitive Analysis & Benchmarks

Related Providers

Nearby Providers

Frequently Asked Questions

References